Cytarabine also stimulated LC3 conversion and p62 degradation in HL-60 and PBMC from CML patients, without increasing beclin-1 expression (Fig. 3A, B). This evidence concerns the gene MAP1LC3A and chronic myelogenous leukemia, BCR-ABL1 positive.